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ABSTRACT Pregnant Wistar rats were injected with hydroxyurea (HU) in- 
traperitoneally (IP) at one of several 6-hour intervals on days 9-10.75 to study 
the role of circadian growth variations in the teratologic response of the fetuses. 
Two stocks of rats were studied and the results in each compared. The fetal re- 
sponse to HU, as observed at day 21, was not detectably modified by circadian fe- 
tal growth variation. No correlations between hour of HU administration and 
fetal weight, placental weight, resorption, or total malformation rates were found. 
Cyclic variations in the incidence of hydronephrosis and left umbilical artery was 
observed, but it was not clear that these were related to maternal light:dark 
cycles. Differences of response between two stocks of rats included marked varia- 
tion in the incidence and type of malformations and variations in the timing of 
peak incidence for some but not all malformations. 
Fetal growth of rats in late gestation shows 
a circadian rhythm in which rapid growth oc- 
curs during the dark phase of the daily cycle 
and slow growth during the light phase (Barr, 
'73b). The discovery of this phenomenon 
raised the question of whether or not circadian 
growth rhythms occur during organogenesis. 
If growth rhythms do occur during organo- 
genesis, a corollary question is: Can they be 
detected by timed teratogen administration 
and examination of the near-term fetus? A 
teratogen with rapid onset of action and rapid 
elimination was sought to test the relations 
between the time of teratogen administration, 
fetal growth, and production of malformation. 
Hydroxyurea (HU) was chosen as an appropri- 
ate agent since it is (1) teratogenic in rats 
(Chaube and Murphy, '66), (2) rapidly acting 
(Scott et al., '71) and (3) rapidly eliminated 
(Adamson et al.. '65). If cyclic variation in the 
fetal effects of HU could be demonstrated, it 
would support the hypothesis that circadian 
variations in fetal growth occur during early 
gestation. 
MATERIALS AND METHODS 
Virgin female Wistar rats (155-275 gm) were 
caged overnight with males and examined for 
sperm by vaginal smear. Pregnancy was 
timed for 6 AM (day 0.0) of the day sperm 
were found. Two stocks of rats were tested for 
their responses in parallel experiments be- 
cause different stocks of the same strain of a 
species have been shown to respond variably 
to the same teratogen (Barr, '73a). A-stock 
rats were from a colony maintained by one of 
us (A.R.B.) derived from Wistar stock origin- 
ally from Albino Farms (Red Bank, NJ): 
B-stock animals were CFN Wistar rats pur- 
chased for this study from Carworth (New 
City, NY). 
Pregnant rats were caged individually and 
allowed Rockland rat diet and tap water ad 
libitum. They were exposed to light from 6 
AM to 6 PM. 
Hydroxyurea (HU) (Calbiochem, San Diego, 
CA) was prepared fresh weekly as a 5% (wlv) 
solution in sterile saline for injection and 
stored at 4°C until use. The pregnant animals 
were injected intraperitoneally (IP) at one of 
eight 6-hour intervals from day 9.0 (6 AM) to 
day 10.75 (12 PM). Published reports (Chaube 
and Murphy, '66) and preliminary experiments 
showed that progressively higher doses of HU 
are needed to produce malformation as gesta- 
tion advances. Therefore, the dose was in- 
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TABLE 1. Resorption rates, fetal and placental weights, and malformation rates of offspring of pregnant rats given 
hvdroxvurea on davs 9-10 of gestation. 
Fetal weight Placental weight 
Age treated HU dose Litters Resorbed Fetuses mean f SE mean f SE Malformed 



































4.91 * 0.06 438 f 6 
5.09 * 0.04 497 & 8 
5.26 f 0.05 460 f 8 
5.51 ? 0.05 465 f 7 
5.39 * 0.04 458 f 5 
5.15 k 0.04 432 f 8 
5.35 f 0.05 481 f 11 

















128 4.26 f 0.05 
122 4.10 f 0.06 
116 4.29 f 0.06 
127 4.45 f 0.05 
100 4.41 f 0.05 
122 4.44 * 0.04 
128 4.35 f 0.04 
97 4.29 f 0.04 
397 f 5 78.1 
373 f 5 91.8 
399 f 6 97.4 
392 f 6 93.7 
370 k 6 86.0 
352 f 5 77.9 
355 * 5 62.5 
339 f 5 57.7 
Controls - 27 6.1 340 4.89 f 0.02 405 f 3 3.2 
creased with gestational age: The base dose 
was 200 mg HUlkg maternal weight at day 9.0 
and this dose was increased by 25 mglkg for 
each 6-hour interval beyond day 9.0. Thus, on 
day 10.75 the dose was 375 mg HUikg mater- 
nal weight. 
Control animals, of the B-stock only, re- 
ceived IP  injections of sterile saline at various 
times. Since there was no evidence of devia- 
tion of fetal or placental weight by time of sa- 
line injection, and no malformations, they 
were combined as a single control group re- 
gardless of time of injection. Controls for the 
A-stock were not included since the purpose of 
the study was not to establish the teratogeni- 
city of HU, but only to determine if there was 
a relation between time of dosage and fetal 
outcome. 
The fetuses were delivered by cesarean sec- 
tion between 9 and 10 AM on day 21. Fetal 
blood loss was prevented by electocautery of 
the umbilical cord. The fetuses and placentas 
were cleaned, blotted free of surface moisture, 
weighed, and examined for externally evident 
malformations. After fixation in Bouin’s solu- 
tion, the fetuses were examined for soft tissue 
malformations by a modification of Wilson’s 
(‘65) razor-blade dissection technique. 
Mean fetal and placental weights were 
calculated for each litter and experimental 
subgroup. Comparisons of mean weights were 
made by Student’s t-test. Resorption rates 
were calculated on the basis of experimental 
subgroups, e.g., the percentage of resorptions 
among the total number of implantations in 
the subgroup. The incidence of malformations 
was also cdculated on the basis of subgroup 
totals. Interstock comparisons of resorptions 
and malformations were made by x2 analysis. 
Dose-dependent effects of placental weight 
were measured by regression-correlation 
analysis, least squares method, assuming lin- 
earity of regression. 
RESULTS 
Weights 
HU produced marked depression of fetal 
and placental weights below control values in 
the B-stock rats (Table 1). Whether or not HU 
produced growth retardation in the A-stock is 
unknown since untreated controls were not 
studied. There were significant differences be- 
tween the treated stocks in both fetal and pla- 
cental weights, with the A-stock being a great 
deal heavier than the B-stock (Table 1). In nei- 
ther stock was there any evident association 
between the hour of HU administration and 
fetal weight on day 21. Fetuses were classified 
by malformation and reevaluated for varia- 
tions in weight but no time-dependent associ- 
ations were found. There was a dose-depen- 
dent depression of placental weight in the 
B-stock (r 0.855, df7, P < 0.01) but not in 
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Mortality 
Among the A-stock, previous experience led 
us to expect a normal resorption rate of about 
3%. The observed resorption rate ranged from 
4.2% to 11.5%. The B-stock controls resorbed 
6.1% of implantations, a rate close to that pre- 
viously found with animals from the same 
source. Resorptions in the HU-treated B-stock 
rats varied from 9.4% to 15.9%. No statistical- 
ly significant association between resorption 
rate and hour of injection was found in either 
stock. Incidence curves for resorptions by time 
of HU injection for the two stocks had the 
same shape, with peaks after injection at days 
9.25 and 10.50. 
Malformation 
HU was teratogenic in both stocks of rats. 
However, there were some notable differences 
between the stocks in the types, incidence, and 
timing of the defects produced (Table 2). In ad- 
dition to fetal malformations, several instan- 
ces of placental abnormality were seen, inclu- 
ding gross cysts of the placenta and extremes 
of placental size, both large and small. These 
abnormalities of the placenta had no obvious 
correlation with fetal malformations or fetal 
sue. 
Normally in the rat the right umbilical artery 
persists and the left becomes obliterated dur- 
ing development. In 2.9% of the B-stock con- 
trol fetuses the situation was reversed and the 
left artery persisted. Experience in other stu- 
dies with Wistar rats from several sources sug- 
gests that a left umbilical artery can normally 
be expected in 2-3% of fetuses regardless of 
the source of the stock (unpublished data). Of 
the different subgroups of HU-treated rats 618 
of the A-stock and 818 of the B-stock had an in- 
cidence of left umbilical artery that was signifi- 
cantly (P < 0.05) higher than in controls. 
With the notable exception of hydronephro- 
sis, the incidence of each malformation was 
higher in the B-stock than the A-stock (Table 
2). With a few exceptions, the higher inciden- 
ces in the B-stock were found at every injec- 
tion time compared. Several defects were com- 
mon in the B-stock but uncommon in the 
A-stock. These were protruding tongue, hind- 
limb dysplasia, tail malformations, and anal 
atresia. A-stock rats had a significantly (P < 
0.05) higher incidence of hydronephrosis, ex- 
cept from day - 10.75 HU injection, when the 
difference between the stocks did not reach 
statistical significance. 
In most instances a particular malformation 
was found after a wider range of injection 
times in the B-stock than in the A-stock. For 
example, maxillary hypoplasia was found 
after day 9.0 - 9.5 injection in the A-stock and 
day 9.0 - 10.0 in the B-stock. Another differ- 
ence between the stocks was that the peak in- 
cidence of several malformations occurred 
later, by about 6 hours, in the B-stock. Of 
those malformations for which there were suf- 
ficient data for interstock comparisions, the 
peak incidence of an-Imicrophthalmia, hydro- 
cephaly, and hydronephrosis was produced by 
HU injection 6 hours earlier in the A-stock 
than in the B-stock. 
Data for other malformations were insuffi- 
cient for detailed comparison but were sugges- 
tive of a 6-hour advance in peak incidence in 
the A-stock for facial asymmetry, maxillary 
hypoplasia, micrognathia, clefts of the lip/an- 
terior palate, and exencephaly. Incidence 
curves for pointed mandible and encephalocele 
appeared to be symmetrical between two 
stocks. Occurrences of ear dysplasia, cleft pa- 
late, right diaphragmatic hernia, hindlimb 
dysplasia, tail malformation, and anal atresia 
were too rare in the A-stock to permit inter- 
stock comparisons of peak incidence timing. 
Inspection of incidence graphs for resorp 
tions, left umbilical artery, and hydronephro- 
sis suggested a cyclic factor in their occur- 
rence. The data were summed for hour of injec- 
tion, disregarding day of injections, and x2 
analyses were performed. In a 4 X 2 format (6 
AM, 12 AM, 6 PM, 12 PM) there were no signifi- 
cant deviations from expected distributions 
for resorptions in either stock. For left umbili- 
cal artery the difference between the observed 
and expected distribution approached but did 
not reach statistical significance in both 
stocks (0.10 > P > 0.05). In both stocks the 
distribution of fetuses with hydronephrosis by 
hour of HU injection was significantly 
different from expected values (A-stock, P < 
0.0005; B-stock, P < 0.01). When the data 
were analyzed in a 2 X 2 format, by combining 
adjacent hours of injection, it was found that 
the A-stock had a significant excess of fetuses 
with hydronephrosis after HU injection at 12 
AM + 6 PM (P < 0.0005). The B-stock had a s ig  
nificant excess of fetuses with hydronephrosis 
following injections at 6 PM + 12 PM (P < 
0.01). As was suggested from the data for 
other malformations, there appeared to be a 
6-hour advance in the time of maximum sensi- 
tivity to HU-induced hydronephrosis in the 
A-stock compared to the B-stock. 
DISCUSSION 
Fetal rats have been shown to exhibit a cir- 
cadian variation in growth rate during late 
gestation (Barr, '73b). A phase of rapid growth 
occurs during the night, followed by a phase of 
slow growth during the day. Marked fluctua- 
tions of body weight in adult rats, pregnant 
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and nonpregnant, during a 24-hour period cor- 
relate well with feeding and activity cycles 
which in turn seem to be regulated by environ- 
mental lighting (Slonaker, '12; Barr, '73b). I t  is 
not yet known how early in gestation diurnal 
fluctuations in fetal growth occur. We are un- 
aware of any published data on the specific 
question of circadian variations of cell prolifer- 
ation in the normal embryo in vivo. Scott et al. 
('71) measured DNA synthesis sequentially for 
29 hours in normal rat embryos as controls for 
HU-treated embryos. Their data indicate that 
the rate of DNA synthesis had a diurnal fluc- 
tuation in the day-12-13 embryo. 
Hydroxyurea inhibits DNA synthesis, pro- 
ducing mitotic arrest or cell death (Philips et 
al., '67). When HU levels drop below threshold 
values, DNA synthesis and division resume in 
the surviving cells which appear to be syn- 
chronized (Scott et al., '71). HU is an appropri- 
ate agent to test for the presence of diurnal 
variations in embryonic cell division since it 
produces maximal DNA synthesis inhibition 
in the rat fetus within 5 hours after IP admin- 
istration with a rapid return toward normal by 
11 hours (Scott et al., '71). 
If diurnal variations in cell division rates oc- 
cur in the rat embryo, it would be expected 
that HU given during a phase of rapid cell pro- 
liferation would have more deleterious effects 
than when given during a phase of slower cell 
proliferation. Such effects could be manifest 
as fetal death, malformations, andlor intrau 
terine growth retardation. The search for 
modification of HU teratogenesis by circadian 
rhythms had no clear-cut results. Inspection 
of the incidence curves for left umbilical artery 
suggested a daily rise and fall for this ano- 
maly, but when tested for time-dependent ef- 
fects the variation failed to reach a level of sta- 
tistical significance (0.10 > P > 0.05). In the 
case of HU-induced hydronephrosis, there was 
a cyclic rise and fall in incidence during a 
24-hour period. However, the timing of the 
rise varied by 6 hours between the two stocks, 
despite the fact environmental lighting and 
presumably feedinglactivity cycles were the 
same. This suggests that some phenomenon 
other than light-controlled maternal circadian 
rhythms operates to produce the variation. 
The data from this study do not answer the 
question of whether circadian growth rhythms 
occur during organogenesis. No correlation be- 
tween hour of HU administration and fetal 
weight, resorptions, or total malformation 
rates were found. If circadian embryonic 
growth has an effect on the response to terato- 
gens we were unable to detect it in near-term 
fetuses. We think that if a search for circadian 
growth rhythms in the early embryo is to be 
made it will have to be by direct means and 
not by the indirect means that we tried. 
The data from this study provide some fur- 
ther insights into the nature of interstock vari- 
ability of response to teratogens. There were 
rather great differences in the incidence of 
malformations produced in both stocks and 
some malformations were found almost exclu- 
sively in one stock. There were also differences 
between stocks in the duration of the period 
during which several of the malformations 
could be produced. I t  may be that the sensi- 
tive period was longer in one stock of rats or 
that there was a shift upward in the teratogen- 
ic threshold in the other. 
Another difference in the response of the 
two stocks of rats was an apparent shift in the 
hour of maximum sensitivity to HU terato- 
genesis. A-stock animals appeared to reach 
the time of maximum sensitivity 6 hours 
before the B-stock. In exploiting a teratologic 
model to study a particular malformation, it 
would be advisable to give the teratogen at 
various times of day to determine the time of 
maximum response. The time of maximum re- 
sponse in this study varied from 6 AM to 6 PM. 
Of course the need for such "fine tuning" of 
dosing times would depend greatly on the 
mode of action of the teratogen; those agents 
with a rapid onset of action and prompt eli- 
minationldeactivation would require more pre- 
cise timing. 
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